drugset / Trial / NCT00470496
Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of photodynamic therapy using HPPH in treating patients who are undergoing surgery for primary or recurrent head and neck cancer. Photodynamic therapy (PDT) uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. Giving photodynamic therapy after surgery may kill any tumor cells that remain after surgery.
Timeline
- Start
- 2006-10-19
- Primary completion
- 2011-10-28
- Completion
- 2018-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 2-(1-HEXYLOXYETHYL)-2-DEVINYL PYROPHEOPHORBIDE-A | Unknown | 4 mg/m2 | Intravenous |
Indications
adenoid cystic carcinoma
esthesioneuroblastoma
hypopharynx squamous cell carcinoma
inverted papilloma
larynx verrucous carcinoma
lymphoepithelial-like carcinoma
metastatic squamous cell carcinoma
nasal cavity and paranasal sinus lethal midline granuloma
nasal cavity and paranasal sinus squamous cell carcinoma
nasopharyngeal squamous cell carcinoma
oral cavity mucoepidermoid carcinoma
oropharynx squamous cell carcinoma
salivary gland cancer
skin basal cell carcinoma
thyroid gland follicular carcinoma
thyroid gland papillary carcinoma
verrucous carcinoma of oral cavity